Skip to main content

JDRF has now rebranded to Breakthrough T1D.
Our name has changed, our mission has not.

News

New research highlights the effectiveness of immune therapies for type 1 diabetes

The research, which was co-funded by JDRF, reveals that drugs that target the immune system offer very effective and rapid improvements in stabilising blood sugar levels, often within just three months.
Breakthrough T1D profile picture
Breakthrough T1D staff 6 November 2023

T cell immune system

In a research paper published in the Lancet journal, an international team of researchers combined data from 21 clinical trials of immune therapies, or immunotherapies, which revealed the incredible potential of immunotherapy to treat people newly diagnosed with type 1 diabetes.

Immune therapies target the immune attack

Clinical trials have demonstrated that immunotherapies can interfere with the destruction of insulin-producing cells, called beta cells. Preserving beta cells allows people developing type 1 diabetes to keep making their own insulin for longer. If people with type 1 can produce even a small amount of insulin, their type 1 may be considerably easier to manage, a phenomenon known as the honeymoon phase.

Global team of researchers

The research group includes leading immunologists from Breakthrough T1D UK, Cardiff University, Critical Path Institute, University of Alberta, Colorado University and the pharmaceutical industry including JDRF-funded researcher Professor Colin Dayan. Professor Colin Dayan from Cardiff University said: “This research supports the role of immunotherapy, focusing on preventing the autoimmune destruction of insulin producing cells, rather than simply relying on insulin to treat the resulting insulin deficiency. Potentially screening programs could detect people at high risk of type 1 diabetes, and these treatments could be used even earlier with the ultimate aim of preventing childhood type 1 diabetes.”

 

Delaying type 1 beyond childhood

Currently, immune therapies can delay the onset of type 1 diabetes and the need for insulin treatment. This delay is crucial to limit the prevalence of type 1 in childhood, where the condition can be more challenging to manage due to the hormones involved in puberty. Giving children their childhood back is an exciting possibility thanks to immunotherapy drugs. Combining immune therapies and fine-tuning the drugs offers hope that we could one day halt the immune attack completely.

Importance of C-peptide

C-peptide (short for connecting peptide) is needed to make insulin. Beta cells release C-peptide with insulin in equal amounts, but insulin is used quickly so it is difficult to measure. Measuring the amount of C-peptide in a blood sample is an accurate measure of how much insulin beta cells are releasing.

This new research established the importance of C-peptide as a biological marker of type 1. This offers an effective tool to measure the success of clinical trials and understand how well people are managing their type 1.

Research to reality

The research heralds a new era of type 1 diabetes treatment. We must now help get these powerful drugs into the hands of people who can benefit from them. Joint first author Dr Kimberly Collins, joint lead researcher from the Critical Path Institute said: “The data and analysis performed in this exciting project have provided the basis for an invaluable clinical trial simulation tool to promote faster and more efficient clinical trials in this space.”

Related news

Read more
Scientist researcher woman in white coat using microscope in laboratory
Research
1 July 2025

New trial results show potential protection against kidney damage in young adults  

A recent study has shown that a treatment currently used for type 2 diabetes could be used to help prevent kidney damage in young adults with type 1

Read more
A woman researcher at work in a lab
Research
24 June 2025

Six-month clinical data shows engineered islets can exist without immunosuppression

New data from Sana Biotechnology, in collaboration with Uppsala University Hospital in Sweden, shows that six months post-transplant, one person with type 1 diabetes (T1D) is successfully producing insulin and does not require immunosuppression.

Read more
Vertex Pharmaceuticals logo graphic
Research
23 June 2025

Vertex trial of Zimislecel cellular therapy enables ten of 12 participants to remain insulin independent

US-based company Vertex have published promising figures from their cell therapy trial, showing advancements in stem cell research.

Read more
Two older men at home reading type 1 diabetes information booklets.
Research
17 June 2025

Healthcare systems unprepared for rising number of older adults with T1D

We're calling for urgent reform as new report reveals older people with T1D are systematically failed by health and social care services.

Connect with us on social